期刊文献+

移植肾慢性排斥反应患者治疗前后24h尿蛋白定量、血肌酐及血压水平变化研究

The study on the change of 24h urinary protein,SCr and BP before and after treatment for chronic rejection of kidney transplant patients
原文传递
导出
摘要 目的探讨移植肾慢性排斥反应患者治疗前后24h尿蛋白定量、血肌酐及血压水平变化情况。方法选取行肾移植术后发生移植肾慢性排斥反应的70例患者为实验组,并选取同期行肾移植术后不伴移植肾慢性排斥反应的正常患者70例为对照组。对于发生排斥反应的患者给予冲击治疗和调整免疫抑制剂的剂量逆转排斥反应。将两组患者行肾移植术后的和出院前的24h尿蛋白定量、血肌酐及血压进行研究比较。结果经研究发现,治疗前实验组的24h尿蛋白定量、血肌酐及血压水平明显高于对照组,治疗后降低为基本正常,有显著性差异或有非常显著性差异(P〈0.01)。结论移植肾慢性排斥患者的24h尿蛋白定量、血肌酐及血压水平变化呈现一定的规律性,抗排斥反应治疗可大大改善其水平。研究证明24h尿蛋白定量、血肌酐及血压水平对移植肾慢性排斥反应的临床诊断和治疗具有重要价值。 Objectives To investigate the change before and after treatment of 24h urinary protein ,SCr and BP in chronic rejection of kidney transplant patients. Methods 70 kidney transplant patients in chronic rejection treated with anti - rejection were selected as observation group, and 70 kidney transplant patients without chronic rejection as control group,then the 24h urinary protein,SCr and BP of the two groups before and after the treatment were studied and compared. Results The 24h urinary protein, SCr and BP of the observation group before the treatment were higher than those of control group, and the levels after the treatment at 24 hours declined, and almost equal to those of control group( P 〈 0.01 ). There were significant or very significant differences. Conclusions The change of the 24h urinary protein, SCr and BP in the kidney transplant patients in chronic rejection treated with anti -rejection is regular, chronic rejection combined with the treatment of anti -rejection should decrease the levels.
出处 《国际泌尿系统杂志》 2012年第5期605-606,619,共3页 International Journal of Urology and Nephrology
基金 课题来源:广东省自然科学基金(编号:C03030305)
关键词 肾移植 移植物排斥 蛋白尿 血压 肌酸酐 Kidney Transplantation Graft Rejection Albuminuria Blood Pressure Creatinine
  • 相关文献

参考文献5

二级参考文献32

  • 1于立新.影响同种肾移植长期存活的主要因素[J].广东医学,2004,25(9):997-998. 被引量:2
  • 2于立新,曾京华,付绍杰,罗永礼,姚冰,耿舰,吕士军.穿刺活检和彩色多普勒诊断移植肾亚临床排斥反应的比较[J].广东医学,2004,25(11):1260-1262. 被引量:4
  • 3[1]Wilson AG,Symons JA,McDowell TL,et al.Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.Proc Natl Acad Sci U S A,1997,94(7):3195-3199.
  • 4[3]Racusen,LC,Solez K,Colvin RB,et al.The Banff 97 working classification of renal allograft pathology.Kidney Int,1999,55(2):713-723.
  • 5[4]Turner DM,Williams DM,Sankaran D,et al.An investigation of polymorphism in the interleukin-10 gene promoter.Eur J Immunogenet,1997,24(1):1-8.
  • 6[8]Cuhaci B,Kumar MS,Bloom RD,et al.Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function.Transplantation,1999,68(6):785-790.
  • 7[9]Charpin JM,Valcke J,Kettaneh L,et al.Peaks of transforming growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of chronic rejection.Transplantation,1998,65(5):752-755.
  • 8LEGENDRE C,THERVET E,SKHIRI H,et al.Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients[J].Transplantation,1998,65(9):1506-1515.
  • 9MURUVE N A,STEINBECKER K M,LUGER A M.Are wedge biopsies of cadaveric kidneys obtained at procurement reliable?[J].Transplanthation,2000,69(11):2384-2388.
  • 10KEE T Y,CHAPMAN JR,O'CONNELL P J,et al.Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants[J].Transplantation,2006,82(1):36-42.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部